SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MAXY - Maxygen, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (216)3/13/2007 4:14:18 PM
From: keokalani'nui  Read Replies (2) | Respond to of 262
 
From "IND Mid-07" to loss of partner for failure to agree on a pre-clinical model?

I have to believe maxy would have been willing to waive or postpone the milestone, so there's something else wrong with the program?



To: keokalani'nui who wrote (216)3/13/2007 8:57:55 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 262
 
Endogenous FVIIa is a remarkable substance and it really doesn’t need to be enhanced with clever chemistry, as MAXY was trying to do. What FVIIa does need is a cheaper production method, and this is where the efforts of GTCB and partner LFB are squarely focused.

investorshub.com

(Disclosure: long GTCB; no position in MAXY.)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News